Home » Topics » Patents, BioWorld Science

Patents, BioWorld Science
RSS

CP-122638: Pfizer's potential treatment for non-migraine emesis

July 26, 1996

5-HT3/NK1 antagonist combination effective in emesis treatment and prevention

July 26, 1996

Vanderbilt University describes ligands for 5-HT3 receptors

July 26, 1996

MBP peptide analogues described as multiple sclerosis treatment

July 26, 1996

Yeda claims protein as potential autoimmune disease treatment

July 26, 1996

Chinoin describes new selegiline formulation

July 26, 1996

Raloxifene indicated for excess NPY associated disorders

July 26, 1996

Pierre Fabre reports 5-HT1A agonists

July 26, 1996

Duloxetine claimed for new indication

July 26, 1996

Contrast agents and antidotes described by Schering AG

July 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...